社会政策在预防痴呆症方面的潜力:利用系统审查和元分析进行的生态研究
Yuliya Bodryzlova1, Fereshteh Mehrabi1,2, Anthony Bosson3
1École de santé publique, Université de Montréal, Montreal, Canada.
Journal of aging & social policy
|August 25, 2023
概括
社会政策对阿尔茨海默病 (AD) 的结果产生影响. 较低的收入不平等和更高的医疗保健支出可能会降低没有痴呆症 (ADw/oD) 的AD风险,特别是在中度的大脑病理方面.
科学领域:
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
- 老年学是一门学科.
背景情况:
- 社会政策影响健康决定因素,如教育和心血管健康,影响阿尔茨海默病 (AD) 风险.
- 社会政策与没有痴呆症的阿尔茨海默病 (ADw/oD) 之间的关系仍未得到充分探索.
研究的目的:
- 评估社会政策与没有痴呆症的阿尔茨海默病 (ADw/oD) 的可能性之间的关联.
主要方法:
- 使用系统性审查和元分析进行生态研究设计.
- 包括来自四个数据库的18项研究,以及经济合作与发展组织 (OECD) 的社会政策指标.
- 定义ADw/oD是死亡与AD大脑病理显著但没有临床痴呆症.
主要成果:
- 在ADw/oD (中度AD病理) 和可支配收入,贫困率和公共医疗保健支出的吉尼指数之间发现了逆相关性.
- 患有晚期AD病理的ADw/oD仅与公共长期护理支出有关.
结论:
- 社会政策,包括收入分配和医疗保健支出,可能在患有阿兹海默症的老年人中起到维持认知健康的作用.
- 医疗保健和长期护理的公共开支是潜在的因素,影响了没有痴呆症的AD结果.
相关概念视频
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
Alzheimer's Disease: Overview
518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518
Alzheimer's Disease: Treatment
213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
Cognitive Development During Adulthood
155
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
155
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
152
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
152
Parkinson's Disease: Overview
596
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
596


